SCHEMBL23745232

SCHEMBL23745232

Cn1ccnc1C(=O)CCC(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 1/20 0.39
▸ NAMPT P43490 1/20 0.35
▸ HTT P42858 1/20 0.34
▸ RAB9A P51151 4/20 0.33
▸ ALDH1A1 P00352 4/20 0.33
▸ NPC1 O15118 3/20 0.33
▸ FDPS P14324 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ FPR2 P25090 3/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ POLB P06746 2/20 0.32
▸ TSHR P16473 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ ALOX12 P18054 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18787644 0.87 NAMPT (0.39) NAMPTHTTRAB9AALDH1A1NPC1
SCHEMBL15979655 0.84 NAMPT (0.44) NAMPTHTTRAB9AALDH1A1NPC1
SCHEMBL23745443 0.83 FPR2 (0.39) STING1ALDH1A1KDM4EFPR2SMN1; SMN2
SCHEMBL18366656 0.81 TNF (0.40) ALDH1A1FPR2POLBMAPT
SCHEMBL22040155 0.79 TDP1 (0.43) ALDH1A1KDM4EPOLBMEN1KMT2A
SCHEMBL28839171 0.78 NAMPT (0.38) NAMPTHTTRAB9AALDH1A1NPC1
SCHEMBL21051142 0.78 NAMPT (0.40) NAMPTHTTRAB9AALDH1A1FDPS
SCHEMBL8232530 0.77 KDM4E (0.39) NAMPTALDH1A1KDM4E
SCHEMBL24096159 0.76 NAMPT (0.39) NAMPTHTTRAB9AALDH1A1NPC1
SCHEMBL12934353 0.74 NAMPT (0.40) NAMPTHTTRAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240299360-A1 ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD (CN) 2024-09-12 — — US disclosed
CN-113754635-B Condensed ring compound and preparation method and application thereof 成都康弘药业集团股份有限公司 2024-06-21 — — CN disclosed
CN-115052596-B ADAMTS inhibitor, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-06-14 — — CN disclosed
CN-115052596-A ADAMTS inhibitor, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2022-09-13 — — CN disclosed
WO-2021158626-A1 ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF Eternity Bioscience Inc. (US) 2021-08-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299360-A1 ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF ADAMTS5, ADAMTS4, ADAMTS1 STING1 3885/4885NAMPT 1087/4885HTT 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback